Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:17:23 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:SNDX - SYNDAX PHARMACEUTICALS INC - http://www.sandstormresources.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNDX - Q0.48.79·9.890.79.46-0.21-2.21,901.017,22313,9129.80  9.85  9.2725.05  8.5819:08:58Jul 0215 min RT 2¢

Recent Trades - Last 10 of 13912
Time ETExPriceChangeVolume
19:08:58Q9.47-0.202
19:08:58Q9.46-0.21140
16:20:41Q9.98350.31351
16:12:01Q9.33-0.34400
16:12:01Q9.33-0.34882
16:04:09Q9.46-0.211
16:04:06Q9.46-0.211
16:04:03Q9.46-0.211
16:02:37Q9.46-0.2122
16:02:14Q9.46-0.21227

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-02 16:01U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-06-24 16:01U:SNDXNews ReleaseSyndax Announces FDA Priority Review of sNDA for Revuforj(TM) (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
2025-06-12 12:02U:SNDXNews ReleaseSyndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
2025-06-12 07:00U:SNDXNews ReleaseSyndax Presents New Revuforj(TM) (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
2025-06-05 16:01U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-05-29 07:00U:SNDXNews ReleaseSyndax Announces Participation in June Investor Conferences
2025-05-14 09:30U:SNDXNews ReleaseSyndax Announces Data Presentations at EHA 2025 Showcasing Revuforj(TM) (revumenib) and Niktimvo(TM) (axatilimab-csfr)
2025-05-12 16:01U:SNDXNews ReleaseSyndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
2025-05-08 07:00U:SNDXNews ReleaseSyndax Announces Participation in May Investor Conferences
2025-05-07 16:01U:SNDXNews ReleaseSyndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
2025-05-05 16:01U:SNDXNews ReleaseSyndax Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-02 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-04-28 07:00U:SNDXNews ReleaseSyndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
2025-04-04 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-04-02 07:00U:SNDXNews ReleaseSyndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
2025-03-05 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-03-03 07:01U:SNDXNews ReleaseSyndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-25 07:00U:SNDXNews ReleaseSyndax Announces Participation in March Investor Conferences
2025-02-24 07:00U:SNDXNews ReleaseSyndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
2025-02-04 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)